EGFR and lung carcinoma: In lung cancer patients with loss of EGFR exon 19 with brain metastasis, 11C labeling as a positron emission tomography marker was used to show that erlotinib can pass through the BBB and enter the brain, facilitating observation of treatment efficacy [39].